Examining two cases of immune thrombotic thrombocytopenic purpura associated with COVID-19 vaccine CoronaVac
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...
News Medical6d
Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
The Hindu5d
Inactivated COVID-19 vaccine CoronaVac associated with TTP
A study published in the journal Frontiers of Medicine has found an association between the inactivated COVID-19 vaccine CoronaVac from Sinovac Biotech and immune thrombotic thrombocytopenic purpura ...
headtopics6d
Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
casereports.bmj4d
Thrombotic thrombocytopenic purpura in a patient with adult-onset Still’s disease: report of a rare entity
Thrombotic thrombocytopenic purpura (TTP) is included in the class of thrombotic microangiopathies and manifests clinically as microangiopathic haemolytic anaemia (MAHA), thrombocytopenia and ...
pharmaphorum3d
FDA changes its mind and approves Takeda’s Eohilia
It has chalked up a series of other FDA approvals in the last few months, however, including congenital thrombotic thrombocytopenic purpura (cTTP) therapy Adzynma (ADAMTS13, recombinant ...
pharmaphorum5d
Takeda grabs late-stage haematology drug from Protagonist
for clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP), which affects fewer than 1,000 patients in the US. The drug was cleared by the FDA last year, becoming the first ...
Medscape3d
Immunological Complications of Blood Transfusion
PTP is characterized by the development of severe, sudden and self-limiting thrombocytopenia occurring 5-10 days after a blood transfusion. The recipients always have a history of sensitization ...